Search Results
Showing Results for sodium–glucose cotransporter-2 inhibitors
Polycystic ovary syndrome (PCOS) is a complex, multisystemic condition characterized by reproductive, metabolic and dermatologic manifestations, including hyperandrogenism and ovulatory dysfunction. Despite its prevalence and significant impact on quality of life, PCOS remains underdiagnosed and poorly managed due to its ...
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age and is characterized by hyperandrogenism, anovulation and insulin resistance (IR).1 Women with PCOS have a high risk of developing type 2 diabetes (T2D), dyslipidaemia, hypertension and ...
Dipeptidyl peptidase-4 (DPP-4) is a ubiquitous, multifunctional, 766-amino acid, type 2 transmembrane glycoprotein, which participates in the regulation of metabolic functions, immune and inflammatory responses, cancer growth and cell adhesion.1 It has two forms: the first is a membrane-bound form, which ...
Tirzepatide is a first-in-class novel dual glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (twincretin), formulated as a synthetic peptide containing 39 amino acids based on the native GIP.1 Tirzepatide has a GIP receptor-binding affinity comparable with native GIP and ...
Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1 Closely linked to T2D is metabolic dysfunction-associated steatotic ...
Type 2 diabetes (T2D) is one of the most common chronic noncommunicable diseases, its incidence is exponentially increasing and is one of the leading causes of morbidity and mortality worldwide.1 As of 2021, T2D ranked among the top causes of ...
The incidence of diabetes has increased in recent years, and advances in technology have allowed for multiple ways to predict the outcomes of patients with diabetes, and have improved quality of life and lowered morbidity and mortality.1 For decades, glycated ...
Welcome to the latest edition of touchREVIEWS in Endocrinology, which includes a broad range of articles selected for their evaluation of current practices and research that directly affect endocrinologists as well as being of interest to the wider biomedical community. ...
Over 37 million people in the USA live with diabetes mellitus, equating to over 11% of the population.1 The large majority of these individuals (around 90–95%) have type 2 diabetes (T2D).1 Approximately 40% of patients T2D develop chronic kidney disease (CKD), with CKD ...
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide.1,2 For this reason, early diagnosis and treatment are relevant to prevent the progression of this disease. Currently, the urinary albumin excretion ...
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycaemia resulting from insulin resistance, inefficient insulin secretion and disproportionate glucagon secretion.1 It has been reported to be an expanding global health issue of the 21st century, and one of ...
Chronic kidney disease (CKD) represents one of the greatest future public health challenges due, among other consequences, to its elevated burden on economic and human resources within healthcare systems.1 Moreover, the rapid growth of type 2 diabetes mellitus (T2DM) results ...
Gestational diabetes mellitus (GDM), defined as hyperglycaemia identified after the first trimester of pregnancy that is not clearly overt diabetes, impacts approximately 7% of births in the USA; a percentage that has increased in parallel with the prevalence of both obesity ...
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and ...
Welcome to the latest edition of European Endocrinology. The impacts of the COVID-19 pandemic are being felt throughout the biomedical community, and the association between diabetes and poor prognosis in COVID-19 is of particular interest to endocrinologists. We begin with ...
The International Diabetes Federation (IDF) estimates that 463 million people worldwide suffer from diabetes, 90% of whom have type 2 diabetes mellitus (T2DM), and expects the total healthcare expenditure on diabetes to reach US$ 845 billion by 2045 from US$ 760 billion in 2019.1 People with ...
The coronavirus disease 2019 (COVID-19) pandemic is an occurring global public health crisis due to the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 In December of 2019, a low respiratory tract infection of unknown cause emerged in Wuhan, Hubei Province, ...
Alan J Sinclair1,2 and Angus Forbes2 1. Foundation for Diabetes Research in Older People, Diabetes Frail Ltd, Droitwich Spa, UK 2. Kings College London, Diabetes Clinical Research, London, UK Diabetes is a highly comorbid and complex illness in ageing societies with ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
